Forest Laboratories, Inc. (FRX) Launches STRIDE Patient Support Program For COPD Franchise Products Tudorza® Pressair® And Daliresp®
2/24/2014 9:26:42 AM
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced the launch of the STRIDE (Start Treatment, Real-time Information, Disease Education) patient support program to help those prescribed Tudorza® Pressair® (aclidinium bromide inhalation powder) or Daliresp® (roflumilast) by answering questions they may have about their chronic obstructive pulmonary disease (COPD) treatment. COPD is a progressive and debilitating lung disease characterized by persistent airflow limitation that makes it hard to breathe.
Help employers find you! Check out all the jobs and post your resume.
comments powered by